BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body
Phase 1
Completed
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
- Interventions
- Drug: Elinzanetant (BAY3427080) treatment ADrug: Elinzanetant (BAY3427080) treatment B
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT04845841
- Locations
- 🇩🇪
CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany
A Study Related to the VOYAGER PAD Trial to Learn More About the Target Population for Xarelto in French Patients
Completed
- Conditions
- Peripheral Artery Disease
- Interventions
- Procedure: Lower limb revascularization
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 227613
- Registration Number
- NCT04824729
- Locations
- 🇫🇷
PMSI, Multiple Locations, France
Study of the Influence of Liver Function on Blood Concentrations of Runcaciguat in Participants With Different Degrees of Liver Impairment
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5
- Registration Number
- NCT04820621
- Locations
- 🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 500
- Registration Number
- NCT04813926
- Locations
- 🇺🇸
Cedar Sinai, Los Angeles, California, United States
🇺🇸Northwestern, Chicago, Illinois, United States
🇺🇸UCSF, Fresno, California, United States
A Study to Learn More About How Safe Dienogest is and How Well it Works Under Real World Conditions in Indian Women With Endometriosis
Completed
- Conditions
- Endometriosis Associated Pelvic Pain
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 160
- Registration Number
- NCT04808843
- Locations
- 🇮🇳
Many Locations, Multiple Locations, India
A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5
- Registration Number
- NCT04809805
- Locations
- 🇺🇸
Sarah Cannon Development Innovations, Nashville, Tennessee, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸South Texas Accelerated Research Therapeutics | START San Antonio, San Antonio, Texas, United States
A Trial to Learn How BAY1817080 Moves Into, Through and Out of the Body and How Safe it is in Healthy Chinese Men
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 39
- Registration Number
- NCT04802343
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)
Not Applicable
Completed
- Conditions
- Diabetic Retinopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 70
- Registration Number
- NCT04795726
- Locations
- 🇧🇬
MHAT Sveta Karidad, Plovdiv, Bulgaria
🇧🇬MHAT Hadzhi Dimitar, Sliven, Bulgaria
🇧🇬MHAT Dr. Bratan Shukerov AD, Smolyan, Bulgaria
The Aim of This Study is to Estimate the Discontinuation Rate of Low-dose Levonorgestrel-releasing Intrauterine System Due to Self-reported Unacceptable Menstrual Bleeding Pattern in Spanish Women Who Are Using it for the First Time How Intrauterine System for Long Acting Contraception
Completed
- Conditions
- Hormonal Intrauterine Contraception
- Interventions
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 316
- Registration Number
- NCT04785950
- Locations
- 🇪🇸
Many locations, Multiple Locations, Spain
Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants
Phase 1
Completed
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 52
- Registration Number
- NCT04771390
- Locations
- 🇺🇸
PAREXEL International, Baltimore, Baltimore, Maryland, United States
🇺🇸Parexel International - Los Angeles, Glendale, California, United States
© Copyright 2025. All Rights Reserved by MedPath